Objective: To investigate the effect of Youjiale on maternal and infant outcomes and thyroid function of patients with subclinical hypothyroidism (HYPOthyroidism). Methods: Seventy-six patients with subclinical hypothyroidism during pregnancy admitted to our hospital from January 2018 to March 2021 were selected and divided into two groups according to random number table method, with 38 patients in each group. The control group was treated with thyroxine tablets, and the observation group was treated with Youjiale. The thyroid hormone levels and maternal and infant outcomes of the 2 groups were compared. Results: The total effective rate of observation group was significantly better than control group (P<0.05). TSH in the observation group was significantly lower than that in the control group after treatment (P<0.05). There was no significant difference in FT3 and FT4 between the 2 groups after treatment (P>0.05). Compared with the control group, the incidence of maternal complications in the observation group was significantly decreased, and the difference between the 2 groups was statistically significant (P<0.05). The incidence of maternal complications and perinatal adverse outcomes in the observation group were significantly lower than those in the control group (P<0.05). Conclusion: Youjiale can effectively improve thyroid function, reduce the incidence of maternal complications, and improve maternal and infant outcomes in patients with subclinical hypothyroidism during pregnancy, which is worthy of clinical promotion.